| |
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
Today’s Big NewsJul 10, 2025 |
|
A pipeline-supporting marketing plan that includes proven tools, well-executed tactics, and a clear strategy are key to keeping your pipeline full of qualified leads. Access this valuable resource to discover how your marketing team can support your business development team in three essential areas: audience, storytelling, and performance. Download today!
|
|
| By Gabrielle Masson The FDA has released an "initial batch" of more than 200 complete response letters (CRLs) in efforts to boost transparency. |
|
|
|
By Kevin Dunleavy Renee Gala joins a short list of female biopharma chief executives as she is set to take the reins at Jazz Pharmaceuticals, replacing the company’s co-founder Bruce Cozadd, who in December announced his intention to step down, ending his 16-year run as CEO. |
By Conor Hale Trained on videos of gallbladder removal surgeries, the robot learned how to perform the procedure itself without control from a human operator. |
By Andrea Park Nearly 70 years into her history, Barbie is still undergoing regular makeovers. Her latest, unveiled by maker Mattel this week, represents the first version of the doll depicted as having Type 1 diabetes. |
|
MedTech companies often launch groundbreaking devices, only to face slow adoption due to costly, time-intensive, and difficult-to-scale training. This whitepaper explores how Virtual Reality (VR) is changing that, helping teams engage physicians earlier, accelerate product adoption, and drive stronger commercial outcomes. Download now to learn more.
|
|
By Zoey Becker In non-metastatic hormone-sensitive prostate cancer, Xtandi met the overall survival mark when combined with leuprolide, but it couldn't achieve statistical significance on its own. |
By Nick Paul Taylor AbbVie is paying Ichnos Glenmark Innovation $700 million upfront for a next-generation rival to Johnson & Johnson’s Tecvayli, positioning the Big Pharma to advance a new option for multiple myeloma patients. |
By Noah Tong The Trump administration is clamping down on undocumented immigrant access to many federal health programs, including Head Start and Title X grants. |
By Angus Liu China’s first domestically made nine-valent HPV vaccine is being priced at 499 yuan ($70) per dose, or a roughly 60% discount compared with Merck’s Gardasil 9, according to the state-owned Xinhua News Agency. |
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Zoey Becker The agreement is meant to help bolster affordable supply of the long-acting PrEP drug while Gilead's voluntary licensing program with generics makers gets up and running. |
By Nick Paul Taylor Woven Health Collective has threaded Boundless Life Sciences Group into its organization, acquiring the medical marketing firm to advance its deal-driven growth strategy. |
By James Waldron Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical journey of its copper-based radiopharmaceutical diagnostic and therapeutic offering. |
By Conor Hale The to-be-consolidated unit will harbor BD’s AI work as well as its devices for medication management and patient monitoring. Bilal Muhsin will serve as its president. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
In all the “what if” chatter and fatigue around AI, predictive sales intelligence is a key opportunity that can easily be implemented and scaled to make omnichannel strategies even more potent. Our whitepaper explores the value of this capability, what role it plays in evolving HCP engagement trends, how to implement, and what to look for when engaging new partners and solutions. Download now.
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| |
|
